ASCO Conference Coverage
Filter News By:
Featured News
View all
More News
(ACCCBuzz Blog) June 12, 2020 - At the recent American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, ACCC presented seven abstracts that capture data spanning the organization’s diverse provider education...
(Johns Hopkins) June 10, 2020 - Johns Hopkins Kimmel Cancer Center thoracic cancer and cancer genomics experts reported promising new findings and studies in mesothelioma, lung cancer and melanoma at the annual meeting of the American...
(MedPage Today) June 8, 2020 - Consensus on testing for dMMR/MSI-H, but strategies vary for other biomarkers.
(Medscape Medical News) June 8, 2020 - Continuing adjuvant imatinib (Gleevec, Novartis) for 3 years rather stopping at 1 year in patients with high-risk gastrointestinal stromal tumor (GIST) could halve the death rate over 10 years,...
(BioPharma Dive) June 5, 2020 - The China-based cell therapy developer, whose myeloma therapy is a rival to one from Bristol Myers and Bluebird, outraised this year's previous top initial biotech stock offering.
(Medscape Medical News) June 4, 2020 - The world's largest oncology meeting went online to mixed reviews. Doubts and hopes coexist about an in-person meeting next year.
(MedPage Today) June 3, 2020 - Response rates of 70-100% with BCMA-targeted products for heavily treated disease.
(MedPage Today) June 3, 2020 - Overall response rate of 36% with tumor-infiltrating lymphocytes in heavily treated patients.
(UPI/HealthDay News) June 3, 2020 - Screening for breast and ovarian cancer genes might be added to the list of medical tests that can be safely and effectively done from home, new research suggests.
(WebMD/Medscape Medical News) June 2, 2020 - The proton pump inhibitor (PPI) omeprazole used with chemotherapy may help shrink tumors in patients with triple-negative breast cancer.

OBR Tweets

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20 https://t.co/NerWJUf67S